Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Prostate Cancer
100%
Local Therapy
100%
Androgen
100%
Prostate Specific Antigen
100%
Biochemical Recurrence
100%
Pilus
33%
Flutamide
33%
Quality of Life
16%
Controlled Clinical Trial
16%
Survival Rate
16%
Median Survival Time
16%
Recurrent Disease
16%
Cancer Therapy
16%
Diarrhea
16%
Overall Survival
16%
Quality of Life Assessment
16%
Morbidity
16%
Functional Assessment
16%
Transaminase
16%
Steroid 5alpha Reductase Inhibitor
16%
Antiandrogen
16%
Testosterone
16%
Antigen Response
16%
Gynecomastia
16%
Androgen Suppression
16%
Treatment Outcome
16%
Median Follow Up
16%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Androgen
100%
Prostate Specific Antigen
100%
Biochemical Recurrence
100%
Finasteride
33%
Flutamide
33%
Malignant Neoplasm
16%
Controlled Clinical Trial
16%
Survival Rate
16%
Median Survival Time
16%
Recurrent Disease
16%
Diarrhea
16%
Aminotransferase
16%
Overall Survival
16%
Antiandrogen
16%
Morbidity
16%
Steroid 5alpha Reductase Inhibitor
16%
Testosterone
16%
Gynecomastia
16%
Neuroscience
Androgen
100%
Prostate Specific Antigen
100%
Finasteride
33%
Flutamide
33%
Quality of Life
33%
Testosterone
16%
Antiandrogen
16%
5-Alpha-Reductase Inhibitor
16%
Transaminase
16%
Keyphrases
Prostate-specific Antigen Progression
25%